Noren Biopharm Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets %
About Noren Biopharm
Noren Biopharm Private Limited (NBPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 June 2015 (Nine years and seven months 22 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sandeep Deshmukh and Tejsinh Deshmukh serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233MH2015PTC265994
-
Company No.
265994
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Jun 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Noren Biopharm?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Deshmukh
|
Director | 25-Jun-2015 | Current |
|
Tejsinh Deshmukh
|
Director | 16-Apr-2018 | Current |
Financial Performance of Noren Biopharm.
Noren Biopharm Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Noren Biopharm?
In 2017, Noren Biopharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Khalyan Agritech Private LimitedSandeep Deshmukh is a mutual person
-
Khushboo Med-Tech Private Limited
Sandeep Deshmukh and Tejsinh Deshmukh are mutual person
-
Universal Caritas Foundation
Tejsinh Deshmukh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Noren Biopharm?
Unlock and access historical data on people associated with Noren Biopharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Noren Biopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noren Biopharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
